

# The Epidemiology of Bile Acid Diarrhea in Denmark [Letter]

Elanda Fikri <sup>1,2</sup>

<sup>1</sup>Department of Environmental Health, Poltekkes Kemenkes Bandung, Bandung, Indonesia; <sup>2</sup>Center of Excellence on Utilization of Local Material for Health Improvement, Bandung Health Polytechnic, Bandung, Indonesia

Correspondence: Elanda Fikri, Department of Environmental Health, Poltekkes Kemenkes Bandung, Jl.Pajajaran 56, Bandung, Jawa Barat, Indonesia, Email elandafikri@yahoo.com

## Dear editor

We were very impressed with the article entitled “The Epidemiology of Bile Acid Diarrhea in Denmark”. The results of this research have advantages, namely: 1) Identify individuals with bile acid diarrhea (BAD) in Denmark using data from the national registry, 2) Identify individuals suffering from BAD based on ICD10 diagnosis codes or SeHCAT test followed by prescription of bile acid binders within a period of 365 days, 3) Show differences in the frequency of BAD diagnosis in different regions of Denmark, 4) Provide information on the characteristics of individuals suffering from BAD, including lower education level, lower income, and higher number of contacts with health services compared to a comparable control group, 5) Track the use of liraglutide as a potential therapy for BAD.<sup>1</sup>

However, we have also discovered several limitations that need to be corrected in the future, namely: 1) The use of a combination of SeHCAT testing and prescription of bile acid binders over a 365-day period to identify individuals with BAD may not include the entire population who actually have BAD. Some individuals with BAD may not have undergone the SeHCAT test or received alternative treatment, so they will not be identified in this study, 2) The ICD10 diagnosis codes for BAD will only be used starting in 2021, so the validity and consistency of using these codes prior to that year is limited, 3) Although the study tracked the use of liraglutide as a potential therapy for BAD, it did not provide information on the effectiveness or safety of liraglutide in the treatment of BAD, 4) The study findings cannot be directly generalized to populations outside Denmark due to differences in health systems, clinical practices, and population characteristics.

To obtain better results, we recommend that further research be carried out by 1) Further validate the definition of BAD used in this study by comparing it with SeHCAT test results and other clinical data to ensure that it covers the entire population with BAD, 2) Conduct prospective studies involving direct data collection from individuals with BAD, including information on symptoms, diagnostic test results, response to treatment, and quality of life, to gain a more in-depth understanding of the characteristics and experiences of individuals with BAD,<sup>2</sup> 3) Conduct further analysis of risk factors associated with BAD, including the relationship with other comorbid conditions, including associations with other comorbid conditions, genetic factors, and environmental factors, to better understand the pathophysiology and epidemiology of BAD,<sup>3</sup> 4) Conduct comparative studies comparing the effectiveness and safety of various therapies for BAD, including bile acid binders and other therapies such as liraglutide, to help guide optimal treatment options.

## Disclosure

There is no conflict of interest related to this communication.

## References

1. Kårhus ML, Ellegaard AM, Winther-Jensen M, Hansen S, Knop FK, Kårhus LL. The epidemiology of bile acid Diarrhea in Denmark. *Clin Epidemiol*. 2023;15:1173–1181. doi:10.2147/CLEP.S442054

2. BouSaba J, Sannaa W, McKinzie S, et al. Impact of bile acid diarrhea in patients with diarrhea-predominant irritable bowel syndrome on symptoms and quality of life. *Clin Gastroenterol Hepatol*. 2022;20(9):2083–2090. doi:10.1016/j.cgh.2021.11.035
3. Farrugia A, Arasaradnam R. Bile acid diarrhoea: pathophysiology, diagnosis and management. *Frontline Gastroenterol*. 2020;12(6):500–507. doi:10.1136/flgastro-2020-101436

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Epidemiology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Epidemiology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

## Clinical Epidemiology

Dovepress

### Publish your work in this journal

Clinical Epidemiology is an international, peer-reviewed, open access, online journal focusing on disease and drug epidemiology, identification of risk factors and screening procedures to develop optimal preventative initiatives and programs. Specific topics include: diagnosis, prognosis, treatment, screening, prevention, risk factor modification, systematic reviews, risk & safety of medical interventions, epidemiology & biostatistical methods, and evaluation of guidelines, translational medicine, health policies & economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: <https://www.dovepress.com/clinical-epidemiology-journal>

<https://doi.org/10.2147/CLEP.S454145>